Avlayah—ERT for Hunter Syndrome

Introduction

In late March 2026, the FDA approved Avlayah (tividenofusp alfa-eknm) for the treatment of pediatric patients with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome. For decades, standard treatments like Elaprase could treat the body’s organs but were unable to reach the brain. Avlayah is a “transport vehicle” biologic; it uses a specialized protein to “trick” the blood-brain barrier into letting the enzyme pass through. In the US, this is being hailed as a historic shift, as it is the first medication designed to address the progressive cognitive decline that affects many children with this condition.

The “Trojan Horse” Mechanism

Avlayah is engineered using ETV (Enzyme Transport Vehicle) technology.

• The Problem: The brain is protected by a strict blood-brain barrier that blocks most medications, including standard enzyme therapies.
• The Solution: Avlayah binds to transferrin receptors (which naturally transport iron into the brain). By hitching a ride on these receptors, the drug “sneaks” into the central nervous system.
• The Result: It reduces toxic heparan sulfate levels directly in the brain and cerebrospinal fluid, potentially slowing or stopping cognitive loss.

The April 2026 “Infusion” Protocol

US metabolic centers are currently transitioning eligible patients to Avlayah using these updated clinical steps:

1. Weekly Administration: Like previous therapies, Avlayah is given as a weekly intravenous (IV) infusion.
2. Cognitive Baseline: Before starting, 2026 US guidelines require a comprehensive neuropsychological evaluation to track cognitive stability over time.
3. Biomarker Tracking: Doctors are now measuring “CSF heparan sulfate” via lumbar puncture or specialized blood tests to confirm the drug is successfully reaching the brain.

Quick Clinical FAQ (April 2026)

1. Is Avlayah a cure? No. It is an enzyme replacement therapy that must be taken long-term to prevent the buildup of toxic sugars (GAGs) in the body and brain.
2. Can my child switch from Elaprase? Yes. Many 2026 US specialists are recommending the switch for patients who show signs of “neuronopathic” (brain-involved) Hunter Syndrome.
3. What are the side effects? The most common are infusion-related reactions (fever, rash, chills). Because it targets the brain, clinicians also monitor for any temporary changes in behavior or sleep during the first month.
4. Is it a “Permanent” approval? It received Accelerated Approval based on biomarker data. The manufacturer must continue studies to prove long-term cognitive benefits to maintain FDA status.
5. What age can start Avlayah? In April 2026, it is approved for pediatric patients, with ongoing trials for infants as young as 4 months.
6. Will insurance cover it? As an “Orphan Drug,” it is covered by most major US insurers and Medicaid, though it requires “Prior Authorization” from a geneticist or metabolic specialist.
7. Does it help with joint stiffness? Yes. Since it circulates throughout the body, it treats both the brain and the physical symptoms (stiff joints, enlarged liver, heart issues).
8. How long is the infusion? Typically 2 to 4 hours, depending on the child’s weight and how well they tolerate the medicine.
9. Why is it called ‘tividenofusp’? This is the international non-proprietary name (INN) reflecting its unique fusion-protein structure.
10. Can DrGuide’s AI Pharmacist find an infusion center? Yes! Our AI can help you locate US hospitals and “Centers of Excellence” equipped to administer Avlayah in 2026.